Monday, July 23, 2012 2:37:16 AM
CYTK DD post at $.73. This nasdaq company has been reporting strong institutional interest via filings within the past two weeks. Eastern Capital, Biotechnology Value Fund, & T. Rowe Price Associates.
Company has 39m shares in the float & 77M O/S. 52wk low is $.57 and 52wk high is $1.45. Most of the buying is occurring near its 52wk lows. Company has 43M in cash & zero debt while the market cap is only 55M. Has $.56 cash per share & $.54 book value per share.
This is a good stock whether you want to go long or short. There will be many opportunities here with all the activities this company has going for it.
Needham Has Buy 2-Jul-12 09:31 am...Briefing.com
-Needham initiates CYTK with a Buy and price target of $2.50 after CYTK recently raised $60 million to advance wholly owned CK357 into a Phase IIb trial in amyotrophic lateral sclerosis as early as 4Q:12. CK357 has shown encouraging functional improvement in ALS patients. While a difficult indication, ALS does provide a potentially fast path to market and a near-term partnership opportunity. CyOmecamtiv could be in pivotal trials next year. Amgen covers all omecamtiv development costs while Cytokinetics has double-digit royalties and a North American co-promotion option on this venture, which the firm believes is a potential blockbuster.
http://finance.yahoo.com/q/bc?s=CYTK&t=my&l=on&z=l&q=l&c=
Eastern Capital 11% stake with 14.3M shares on July 2nd.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8698156
Biotechnology Value Fund reports passive stake of 10% with 13.7M shares on July 3rd.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8704496
T. Rowe Price reports 14.8% stake with 21m shares on July 10th.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8711664
Company has 39m shares in the float & 77M O/S. 52wk low is $.57 and 52wk high is $1.45. Most of the buying is occurring near its 52wk lows. Company has 43M in cash & zero debt while the market cap is only 55M. Has $.56 cash per share & $.54 book value per share.
This is a good stock whether you want to go long or short. There will be many opportunities here with all the activities this company has going for it.
Needham Has Buy 2-Jul-12 09:31 am...Briefing.com
-Needham initiates CYTK with a Buy and price target of $2.50 after CYTK recently raised $60 million to advance wholly owned CK357 into a Phase IIb trial in amyotrophic lateral sclerosis as early as 4Q:12. CK357 has shown encouraging functional improvement in ALS patients. While a difficult indication, ALS does provide a potentially fast path to market and a near-term partnership opportunity. CyOmecamtiv could be in pivotal trials next year. Amgen covers all omecamtiv development costs while Cytokinetics has double-digit royalties and a North American co-promotion option on this venture, which the firm believes is a potential blockbuster.
http://finance.yahoo.com/q/bc?s=CYTK&t=my&l=on&z=l&q=l&c=
Eastern Capital 11% stake with 14.3M shares on July 2nd.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8698156
Biotechnology Value Fund reports passive stake of 10% with 13.7M shares on July 3rd.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8704496
T. Rowe Price reports 14.8% stake with 21m shares on July 10th.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8711664
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
